Thioridazine elicits potent antitumor effects in colorectal cancer stem cells

  • Authors:
    • Chen Zhang
    • Ping Gong
    • Pengfei Liu
    • Ning Zhou
    • Yulai Zhou
    • Yi Wang
  • View Affiliations

  • Published online on: December 14, 2016     https://doi.org/10.3892/or.2016.5313
  • Pages: 1168-1174
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

As a member of the phenothiazine family, thioridazine (THIO) is a potent anti-anxiety and anti-psychotic drug. Recent studies have reported that THIO could suppress the growth of several types of cancer cells. However, the effect of THIO on colorectal cancer stem cells (CSCs) has not been investigated. In the present study, we examined the effect of THIO on viability of CSCs isolated from the human colon cancer cell line HCT116 and its colony-formation ability, along with its stem cell-specific gene expression. The CSCs, EpCAM+ and CD44+ subpopulations from HCT116 cells were isolated using immunomagnetic beads. After incubation with several concentrations of THIO, we evaluated the proliferation and invasion ability of colon CSCs, as well as cell apoptosis. We found that THIO significantly suppressed the proliferation and invasion of colon CSCs and induced cell apoptosis in a concentration-dependent manner. The expression of some apoptosis genes (Bax and caspase-3) was upregulated after treatment with THIO, while that of the anti-apoptosis gene Bcl-2 was downregulated. Moreover, the CSC mitochondrial membrane potential was downregulated. Overall, this study showed that THIO inhibits the proliferation of CSCs derived from the HCT116 cell line through induction of apoptosis, and thus, could be a promising agent for the treatment of colon cancer and worthy of exploring in prospective clinical studies.

Introduction

Thioridazine (10-[2-(1-methyl-2-piperidyl)ethyl]-2-methyl-thiophenothiazine, THIO), a member of the phenothiazine family, was originally used to treat psychotic disorders such as psychosis and schizophrenia (13). In addition, in advanced cancer patients, this drug has been used to treat cancer-related sweating (4,5), as well as depression (6). In recent years, however, some studies have demonstrated that THIO could inhibit the growth of some cancer cell lines (714). It has also shown selectivity for cancer stem cells (CSCs), such as leukemic cancer stem cells (15), glioblastoma stem cells (3) and breast cancer stem cells (16). Thus, THIO is currently regarded as a drug with potential usefulness in anticancer chemotherapy (9,17).

Recent evidence suggests that cancer development is mainly driven by a rare population of cells, the CSCs (16,17). Moreover, some scientists argue that conventional chemotherapeutics are ineffective against human CSCs (18). Therefore, the development of new drugs targeting CSCs holds special significance in clinical cancer research. Sachlos et al (15) demonstrated that THIO could selectively target neoplastic cells and impair human somatic CSCs capable of in vivo leukemic disease initiation without any effect on normal blood stem cells. Their study identified the potential of THIO to target CSCs directly. However, its exact effect on CSCs of other types of cancers still requires further investigation.

Colon cancer is one of the most prevalent cancers, with incidence rates that have been increasing steadily worldwide (19,20). In recent years, despite a series of remarkable advances in colon cancer chemotherapy, the increased resistance to anticancer drugs has been a serious obstacle to the efficient treatment of the disease. Overcoming drug resistance and targeting CSCs are key for the improvement of chemotherapy response (15,20,21). Therefore, the development of novel effective drugs for colon cancer is urgently required.

In this study, we mainly investigated the anti-proliferation and anti-invasion effects of THIO on CSCs isolated from a human colon cancer cell line (HCT116) and further determined the underlying mechanisms. These findings may contribute to the development of THIO-based chemotherapy for patients with colon cancer resistant to traditional anticancer drugs.

Materials and methods

Cell lines and culture

The human colon cancer cell line HCT116 and the human lung fibroblast cell line HELF were obtained from the Cell Bank of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). HCT116 and HELF cells were maintained in RPMI-1640 medium (Gibco/Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco) and penicillin-streptomycin mixed solution. The CSCs isolated from HCT116 cells were cultured in DMEM/F12 medium (Gibco) with 10 µg/ml EGF (Sigma-Aldrich, St. Louis, MO, USA), 10 µg/ml bFGF (Sigma-Aldrich) and 1% B27 supplement (Gibco). The media were changed every other day. The cells were incubated in a humidified incubator with 5% CO2 at 37°C, and were passaged by a dilution of 1:3 every 4 or 5 days.

EpCAM+ and CD44+ cell selection

The cell selection method followed the protocol published by Zhang et al (21). Briefly, HCT116 cells were rinsed with phosphate-buffered saline (PBS) and detached with trypsin at 37°C. After centrifugation, cells were first incubated with anti-human CD44 monoclonal antibody conjugated with biotin (eBioscience, Inc., San Diego, CA, USA), and then fractionated using a CELLection Biotin Binder kit (Invitrogen, Carlsbad, CA, USA), according to the manufacturers recommendations. The isolated cells were further incubated with anti-human EpCAM monoclonal antibody conjugated with biotin (eBioscience) and positive cells were then isolated with the same kit. Cells were cultured in CSC medium, and the purity of such CSCs was evaluated by flow cytometry and immunohistochemistry.

Flow cytometric analysis

The CSCs were dissociated into single cells, further fixed with fixation buffer (eBioscience) and prepared at a concentration of 2.0×106/ml of PBS. Anti-human CD44 antibody conjugated with FITC (BD Biosciences, San Jose, CA, USA) and anti-human EpCAM antibody conjugated with PE (BD Biosciences) were added and incubated for 30 min at 4°C. After washing twice with PBS, the cells were acquired and analyzed by FACScalibur (BD Biosciences).

Immunohistochemistry

The single CSCs were seeded into plates covered in Matrigel and cultured for 24 h. They were fixed in 4% formaldehyde for 20 min at 4°C and permeabilized with 0.1% Triton X-100 for 10 min at 25°C. For immunohistochemistry, the primary antibodies used were anti-human CD44 monoclonal antibodies (1:50; eBioscience) and anti-human EpCAM monoclonal antibodies (1:50; eBioscience). After 12–14 h of incubation at 4°C, samples were washed three times with PBS and processed using an ABC kit and DAB solution (both purchased from Vector Laboratories, Inc., Burlingame, CA, USA). Finally, the sections were imaged with an Axio Scope A1 and AxioCAM MRc 5 (Carl-Zeiss, Oberkochen, Germany).

Colony formation assay

The CSCs were dissociated into single cells and seeded into a 96-well plate at a concentration of 0.5 cells/well. Briefly, the cell suspension was diluted at concentration of 50 cells/ml and 100 µl of cell suspension was added into each well. As a result, there is 1 cell or 0 cell seeded into each well. We observed and imaged cell cloning. The plate was incubated in a humidified incubator with 5% CO2 at 37°C and half of the medium was changed every 3 days. Colonies gradually formed over the next 3 weeks.

Inhibitory effects of THIO on cell proliferation

In order to analyze the anticancer effect of THIO on CSCs derived from HCT116 cells, a CCK-8 assay was performed. In order to explore the effect of THIO on fibroblast cells, representing one of the largest amount of cells in humans, HELF cells were also selected in CCK8-assay. The cells were seeded in 96-well plates at a concentration of 1.0×105 cells/well, and were treated with THIO (Sigma-Aldrich) at different concentrations (0, 10, 20 or 50 µM) for 24 h. The medium without any cells was used as the blank group, while 100 µM cisplatin (DDP) was used as the positive control group. The proliferation index of each group was determined using the Cell Counting kit-8 (CCK-8; Dojindo Laboratories, Tokyo, Japan) according to the manufacturers instructions (21). In brief, 10 µl of CCK-8 solution was added into each well (containing 100 µl of medium) and cultured for 1–2 h at 37°C. The absorbance at 450 nm, which was directly proportional to the number of living cells, was observed for each group (n=4). The inhibition ratio was used to measure cell proliferation in the present study and it was described as (absorbance of 0 µM group - absorbance of each experimental group)/(absorbance of 0 µM group - the absorbance of the blank group).

Cell invasion assay

To assess cell invasion, a Transwell system was used (pore size: 8 µm; Corning, Inc., Corning, NY, USA) following the manufacturers protocol. The CSCs were seeded onto the upper insert covered with Matrigel at a concentration of 1×105 cells per insert in serum-free medium. Outer wells were filled with RPMI-1640 medium containing 10% FBS as a chemoattractant. Then, cells were incubated for 48 h at 37°C. Non-invading cells were removed by swabbing the top layer, and cells able to migrate through the gel and attach to the lower surface of the membrane were stained with crystal violet. The number of cells in four randomly selected microscopy fields was counted for each filter.

Real-time qPCR

Total RNA was extracted using TRIzol reagent (Invitrogen). For each sample, RNA (2 mg) was reverse-transcribed using an RT-PCR kit (Takara, Shiga, Japan), and qPCR was performed with a Thermal Cycler Dice™ Real-Time System and SYBR-Green Premix EX Taq™ (Takara). In the present study, GAPDH was used for qPCR normalization, and all measurements were performed in triplicate. The primer sequences used (5→3) are shown in Table I.

Table I.

Real-time qPCR primer sequences.

Table I.

Real-time qPCR primer sequences.

GenePrimer sequence (53)
NanogF: ATGCCTGTGATTTGTGGGCC
R: GCCAGTTGTTTTTCTGCCAC
CLDN-6F: GCCAGATGCAGTGCAAGGTGT
R: GATGACAAAGACAATCCCAGAGGTG
BaxF: TAACCAAGGTGCCGGAACTGA
R: GGGAGGAGTCTCACCCAACCA
Caspase-3F: CATGGAAGCGAATCAATGGACT
R: CTGTACCAGACCGAGATGTCA
Bcl-2F: GGGGAGGATTGTGGCCTTCTTT
R: TAATGTGCAGGTGCCGGTTCAG
GAPDHF: ACCACAGTCCATGCCATCAC
R: TCCACCACCCTGTTGCTGTA

[i] F, forward; R, reverse.

Western blotting

Western blotting was carried out to test for cleaved caspase-3 using the same protocol as the one we reported in a previous publication (21). Briefly, cells were lysed with lysis buffer (50 mM Tris pH 7.0, 1 mM EDTA, 150 mM NaCl, 1% NP40, 10 mM NaF, 1 mM Na3VO4) containing protease inhibitor cocktail (Roche, Basel, Switzerland), and protein concentrations were determined using a BCA assay kit (Beyotime Institute of Biotechnology, Nanjing, China). Protein bands were separated by electrophoresis in a 12% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and electroblotted onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). After blocking them with 4% non-fat dry milk in Tris-buffered saline (TBS), the membranes were incubated overnight at 4°C with primary antibodies (rabbit anti-caspase-3; Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:1,000 in TBS. They were washed three times with TBS containing 0.5% Tween-20, and then incubated for 1 h at 25°C with secondary antibodies conjugated with a 1:5,000 dilution of horseradish peroxidase (HRP) in TBS. Membranes were then washed three times in TBS containing 0.5% Tween-20 at 25°C. Finally, protein bands were visualized on X-ray film using enhanced chemiluminescence (ECL; GE Healthcare, Bethesda, MD, USA).

Analysis of cell apoptosis

To analyze cell apoptosis, acridine orange/ethidium bromide (AO/EB) staining and Annexin V-FITC/PI staining were used according to the manufacturers instructions (BD Biosciences). Moreover, to determine the effect of THIO on mitochondrial membrane potential in CSCs, JC-1 apoptosis detection kit (BD Biosciences) was used according to the manufacturers instructions and assessed by fluorescence-activated cell sorting (FACS).

Statistical analysis

Statistical analysis was performed with the SPSS 17.0. The results are expressed as mean ± SEM. The differences between the groups were assessed by one-way ANOVA followed by t-tests. P<0.05 was considered statistically significant.

Results

Characterization of CSCs from HCT116 cells

The CSCs isolated from HCT116 formed tumor spheres in suspension when cultured in vitro. Their appearance was distinct from the original HCT116 cells, which were spindle-shaped and grew in adherent state (Fig. 1A). After three to four passages, the cells were further characterized by immunohistochemistry and flow cytometry. The results indicated that the CSCs used in the present study were positive for EpCAM (97.9%) and CD44 (92.7%), while HCT116 cells used as the negative control group displayed a low expression of EpCAM (1.21%) and CD44 (0.87%) (Fig. 1A). To further confirm the colony-forming ability of the CSCs, we separated the CSC spheres into single cells and analyzed their colony-formation ability in 96-well plates. As expected, a single CSC could proliferate and grow; in fact, over 40% of the CSCs formed a tumor sphere after 21 days of single-cell culture (Fig. 1B). In addition, we confirmed that the serum-free condition was necessary for the colony-formation ability and the stem cell-specific gene expression of CSCs. We compared the in vitro cell culture in basal conditions plus 10% FBS and in serum-free conditions. Cultures under FBS conditions could lead to a layer of adherent confluent cells. Compared with HCT116 cells, the CSCs showed a high expression of stem cell-specific genes, NANOG, and CLDN-6 (P<0.05), while downregulation of these genes occurred in the CSCs cultured under FBS conditions (P<0.05) (Fig. 1C). These results suggest that the tumor sphere-like colonies could be obtained from the HCT116 cell line, and that these cells had some stem cell characteristics. In serum-free medium supplemented with EGF and bFGF, the CSCs differentiated even under conditions of an extra-low cell concentration, such as single cell conditions, ruling out the possibility that CSCs may aggregate owing to the high concentration of cells in cultures.

Effect of THIO on the proliferation and invasion of CSCs from HCT116 cells

After treatment with THIO for 24 h at different concentrations, severe morphological alterations were observed in the majority of CSCs cells. We found that the CSCs could still form tumor sphere-like colonies when treated with THIO at 10 µM. However, the number of colonies formed at 10 µM was considerably lower than at 0 µM. No colony formation could be observed at THIO concentrations of 20 µM and above and after treatment with DDP (Fig. 2A).

In vitro invasion assays were performed using CSCs from HCT116 cells treated with THIO in a Transwell system

After crystal violet staining, we observed that the CSC invasion across the membrane from the upper chamber to the lower surface of the membrane was suppressed by THIO. The number of cells on the lower surface of the membrane clearly decreased in the THIO-treated groups at concentrations of 20 and 50 µM, while a slight inhibition of the cell invasion ability was observed in the 10 µM concentration group (Fig. 2B). After counting the number of cells on the lower surface of the membrane, we concluded that THIO could significantly suppress the invasion of CSCs (P<0.05). This effect occurred in a concentration-dependent manner (52.0±8.0 cells for the 0 µM group, 35.6±7.3 cells for the 10 µM group, 22.0±5.4 cells for the 20 µM group, 10.3±4.0 cells for the 50 µM group, and 14.3±3.3 cells for the DDP group) (Fig. 2B).

To further analyze the anticancer effect of THIO on CSCs derived from HCT116 cells, a CCK-8 assay was performed using treated cells (normal human lung fibroblast cell line, HELF cells, HCT116 cells and CSCs). The results indicated that the proliferation of HELF and HCT116 cells was significantly inhibited by THIO at 50 and 100 µM, while that of CSCs was significantly inhibited by THIO at a concentration as low as 1 µM. The inhibition ratio of THIO at 1 and 10 µM was 19.2 and 39.5%, respectively. However, THIO concentrations of 20, 50 and 100 µM exhibited inhibition at very high rates (94.5, 100 and 100%, respectively). The positive control group (10 µM DDP) showed an inhibition rate of 82.7%. Interestingly, THIO at 20 µM did affect the vitality of HELF cells, but the inhibition rate was only 10.6%, while that of CSCs was 94.5% (Fig. 2C). These results indicate that, at a suitable concentration, THIO may be an optimal novel agent for colon cancer treatment. However, further studies are necessary to elucidate the mechanism of action driving this anticancer activity.

Analysis of THIO-induced apoptosis in CSCs

THIO has been reported to induce cervical and endometrial cancer cell apoptosis (7). To detect whether THIO could induce apoptosis in CSCs derived from HCT116 cells, we carried out AO/EB staining. The CSC spheres were labeled by AO/EB after treatment with THIO at different concentrations, and dual staining was examined using confocal microscopy. No significant apoptosis was detected in the negative control group. However, in the group treated with THIO at a concentration of 10 µM, many early-stage apoptotic cells (marked by yellow-green AO nuclear staining) and some late-stage apoptotic cells (marked by orange-red nuclear EB staining) were detected. At higher concentrations (20 and 50 µM), the number of late-stage apoptotic cells was even higher (Fig. 3A). At 50 µM, CSC spheres were much smaller than at lower concentrations, and many single cells could be observed in late-stage apoptosis (Fig. 3A). Further detection by the Annexin V/PI double staining assay revealed that THIO treatment could lead to an increase in the proportion of early-stage apoptotic cells (Annexin V-positive and PI-negative cells), as well as late-stage apoptotic cells (Annexin V-positive and PI-positive cells) in CSCs (Fig. 3B). Further analysis indicated that this induction of apoptosis by THIO occurred in a concentration-dependent manner. The percentage of early-stage apoptotic cells was 5.46, 8.94, 18.8, 40.7 and 14.3% at THIO concentrations of 0, 10, 20 and 50 µM, and DDP treatment, respectively. The percentage of late-stage apoptotic cells was 1.06, 27.4, 32.5, 34.6 and 42.5% at THIO concentrations of 0, 10, 20 and 50 µM, and DDP treatment, respectively (Fig. 3B).

To elucidate the mechanisms of cell apoptosis induced by THIO, cell apoptosis genes and mitochondrial membrane potential were assayed as part of this study. qPCR results indicated that apoptosis genes such as caspase-3 and Bax were significantly upregulated in THIO-treated CSCs (P<0.05), while the anti-apoptosis gene Bcl-2 was significantly downregulated under the same conditions (P<0.05) (Fig. 3C). Moreover, the expression of the caspase-3 gene was confirmed by the western blot analysis. To evaluate the THIO-induced cell apoptosis at the subcellular organelle level, JC-1 staining was carried out to determine the alterations in mitochondria. The percentage of cells with loss of mitochondrial membrane potential increased in a concentration-dependent manner (45.6% for the 0 µM group, 47.6% for the 10 µM group, 51.6% for the 20 µM group, 86.7% for the 50 µM group, and 73.6% for the DDP group) (Fig. 3D). The results suggest that THIO may induce apoptosis in CSCs from HCT116 cells via the loss of mitochondrial membrane potential.

Discussion

THIO has been used in human clinical studies for over 50 years, especially for tuberculosis (TB) therapy (22,23), alleviation of schizophrenia (24) and reduction of pain in cancer (25). In recent years, THIO has been reported to suppress cell proliferation and induce cell apoptosis in several types of cancers (2,7,9,26,27). However, the cytotoxic effect of THIO on colon cancer has not been examined, and the effects of THIO on the viability of CSCs, which are responsible for apoptosis resistance, self-renewal and differentiation, should be investigated thoroughly. The present study revealed that THIO could reduce the viability of CSCs from colon cancer cells (HCT116) and induce apoptosis of CSCs via the mitochondrial pathway. Previous studies in our group revealed that THIO also induces apoptosis in CSCs derived from other cancer cell lines, such as DU145 (human prostate carcinoma cell line) (data not shown). Thus, THIO-based chemotherapy may prove useful in the treatment of various types of cancers. This must be evaluated in future clinical studies.

Although the anticancer effect of THIO has been demonstrated in vivo using mouse models (26,28,29), few clinical trials have been carried out in cancer patients (30) for the complex mechanisms of the THIO anticancer effect to be clearly understood. In the present study, JC-1 results showed that the mitochondrial membrane potential in CSCs was downregulated during apoptosis, which indicates that THIO-induced apoptosis in CSCs may be related to the mitochondrial pathway. In addition to the direct cytotoxic effect on cancer cells, THIO can potentially induce CSC differentiation to overcome neoplastic self-renewal, and compel CSCs to enter the normal cellular lifecycle, via antagonism of D2-family DRs differentially expressed in CSCs (15,31). However, this theory may only apply to a therapy targeting CSCs, and the effect of THIO on CSCs has so far been demonstrated only in human leukemia and breast cancer studies (15,16). Therefore, the specific effects of THIO on CSCs from other cancers, as well as the associated mechanisms, still require exploration.

THIO can prevent the exclusion of some small molecules from cancer cells (26,32,33). This may explain the anti-CSC ability of THIO that was discovered through small-molecule library screening (26,34). A previous study has indicated that THIO could reverse chemoresistance of cancer cells and achieve a significant therapeutic outcome in combination therapy with verapamil (35). A recent study also demonstrated that the combination of THIO and doxorubicin using polymeric micelles might provide a promising strategy for breast cancer treatment by targeting both cancer cells and cancer stem cells (16). Thus, THIO may be useful as a type of adjuvant in combination with other chemotherapeutic drugs.

In clinical studies of cancer, THIO is mainly used for managing depression and psychosis (30). Apart from understanding the therapeutic mechanisms, it is important to consider the optimal dose in order to avoid serious side-effects, which can include movement disorders and cardiac and central nervous system toxicity. Thus, the potential toxic effects of high-dose THIO treatments should be evaluated carefully.

Conclusion, this research showed that THIO could suppress proliferation, reduce invasion, and induce apoptosis in CSCs via the mitochondrial pathway in a concentration-dependent manner. Even though the anticolon cancer effect of THIO still needs to be evaluated in vivo, and in well-designed human clinical trials, there is enough evidence to suggest that THIO may be a promising novel agent as an adjuvant for the treatment of colon cancer, and possibly other cancers.

Acknowledgements

The present study was supported by the Jilin Province Science Foundation (20120960 and 20160204036YY).

References

1 

Zhelev Z, Ohba H, Bakalova R, Hadjimitova V, Ishikawa M, Shinohara Y and Baba Y: Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol. 53:267–275. 2004. View Article : Google Scholar : PubMed/NCBI

2 

Min KJ, Seo BR, Bae YC, Yoo YH and Kwon TK: Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L). Cell Death Dis. 5:e10632014. View Article : Google Scholar : PubMed/NCBI

3 

Cheng HW, Liang YH, Kuo YL, Chuu CP, Lin CY, Lee MH, Wu AT, Yeh CT, Chen EI, Whang-Peng J, et al: Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data. Cell Death Dis. 6:e17532015. View Article : Google Scholar : PubMed/NCBI

4 

Cowap J and Hardy J: Thioridazine in the management of cancer-related sweating. J Pain Symptom Manage. 15:2661998.PubMed/NCBI

5 

Zhukovsky DS: Fever and sweats in the patient with advanced cancer. Hematol Oncol Clin North Am. 16579–588. (viii)2002.viii. View Article : Google Scholar : PubMed/NCBI

6 

Ly KL, Chidgey J, Addington-Hall J and Hotopf M: Depression in palliative care: A systematic review. Part 2. Treatment. Palliat Med. 16:279–284. 2002. View Article : Google Scholar : PubMed/NCBI

7 

Kang S, Dong SM, Kim BR, Park MS, Trink B, Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 17:989–997. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Rho SB, Kim BR and Kang S: A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 120:121–127. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Choi AR, Kim JH and Yoon S: Thioridazine specifically sensitizes drug-resistant cancer cells through highly increase in apoptosis and P-gp inhibition. Tumour Biol. 35:9831–9838. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Lu M, Li J, Luo Z, Zhang S, Xue S, Wang K, Shi Y, Zhang C, Chen H and Li Z: Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis. Onco Targets Ther. 8:1543–1552. 2015.PubMed/NCBI

11 

Gong L, Wang Y, Tong S, Liu L, Niu L, Yuan Y and Bao Y: Mechanism of killing effect of thioridazine on human lung cancer PC9 cells. Zhongguo Fei Ai Za Zhi. 18:727–733. 2015.(In Chinese). PubMed/NCBI

12 

Yin T, He S, Shen G, Ye T, Guo F and Wang Y: Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model. Mol Med Rep. 12:4103–4108. 2015.PubMed/NCBI

13 

Meng Q, Sun X, Wang J and Wang Y: Mechanism of thioridazine plus medroxyprogesterone in the treatment of endometrial cancer. Zhonghua Yi Xue Za Zhi. 95:1540–1543. 2015.(In Chinese). PubMed/NCBI

14 

Liu JK, Hao YJ, Huang JW, Li X, Cai HB and Peng K: Mechanism of thioridazine-induced apoptosis of human colorectal cancer SW480 cells. Nan Fang Yi Ke Da Xue Xue Bao. 35:511–515. 2015.(In Chinese). PubMed/NCBI

15 

Sachlos E, Risueño RM, Laronde S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, et al: Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 149:1284–1297. 2012. View Article : Google Scholar : PubMed/NCBI

16 

Ke XY, Lin Ng VW, Gao SJ, Tong YW, Hedrick JL and Yang YY: Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials. 35:1096–1108. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Dick JE: Looking ahead in cancer stem cell research. Nat Biotechnol. 27:44–46. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Guan Y, Gerhard B and Hogge DE: Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood. 101:3142–3149. 2003. View Article : Google Scholar : PubMed/NCBI

19 

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Kim EJ, Kang JI, Kwak JW, Jeon CH, Tung NH, Kim YH, Choi CH, Hyun JW, Koh YS, Yoo ES, et al: The anticancer effect of (1S,2S,3E,7E,11E)-3,7,11, 15-cembratetraen-17,2-olide(LS-1) through the activation of TGF-β signaling in SNU-C5/5-FU, fluorouracil-resistant human colon cancer cells. Mar Drugs. 13:1340–1359. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Zhang C, Tian Y, Song F, Fu C, Han B and Wang Y: Salinomycin inhibits the growth of colorectal carcinoma by targeting tumor stem cells. Oncol Rep. 34:2469–2476. 2015.PubMed/NCBI

22 

Amaral L, Kristiansen JE, Abebe LS and Millett W: Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother. 38:1049–1053. 1996. View Article : Google Scholar : PubMed/NCBI

23 

Boeree MJ: Global clinical trials for the treatment of TB with thioridazine. Recent Pat Antiinfect Drug Discov. 6:99–103. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Kleibel F: A method of alleviation of pain in cancer patients. Clinical trial of thioridazine (Melleril and Mellerettes) in 251 patients. Munch Med Wochenschr. 103:2341–2343. 1961.(In German). PubMed/NCBI

25 

Smith RC, Baumgartner R, Burd A, Ravichandran GK and Mauldin M: Haloperidol and thioridazine drug levels and clinical response in schizophrenia: Comparison of gas-liquid chromatography and radioreceptor drug level assays. Psychopharmacol Bull. 21:52–58. 1985.PubMed/NCBI

26 

Mu J, Xu H, Yang Y, Huang W, Xiao J, Li M, Tan Z, Ding Q, Zhang L, Lu J, et al: Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. Oncol Rep. 31:2107–2114. 2014.PubMed/NCBI

27 

Tuynder M, Fiucci G, Prieur S, Lespagnol A, Géant A, Beaucourt S, Duflaut D, Besse S, Susini L, Cavarelli J, et al: Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA. 101:15364–15369. 2004. View Article : Google Scholar : PubMed/NCBI

28 

Basta-Kaim A, Budziszewska B, Jagła G, Nowak W, Kubera M and Lasoń W: Inhibitory effect of antipsychotic drugs on the Con A- and LPS-induced proliferative activity of mouse splenocytes: A possible mechanism of action. J Physiol Pharmacol. 57:247–264. 2006.PubMed/NCBI

29 

Park MS, Dong SM, Kim BR, Seo SH, Kang S, Lee EJ, Lee SH and Rho SB: Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts. Oncotarget. 5:4929–4934. 2014. View Article : Google Scholar : PubMed/NCBI

30 

Hercbergs A: Thioridazine: A radiation enhancer in advanced cervical cancer? Lancet. 2:7371988. View Article : Google Scholar : PubMed/NCBI

31 

Gatto F and Hofland LJ: The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer. 18:R233–R251. 2011. View Article : Google Scholar : PubMed/NCBI

32 

Akiyama S, Shiraishi N, Kuratomi Y, Nakagawa M and Kuwano M: Circumvention of multiple-drug resistance in human cancer cells by thioridazine, trifluoperazine, and chlorpromazine. J Natl Cancer Inst. 76:839–844. 1986.PubMed/NCBI

33 

Efferth T and Volm M: Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms. Cancer Lett. 70:197–202. 1993. View Article : Google Scholar : PubMed/NCBI

34 

Sutton LP and Rushlow WJ: The dopamine D2 receptor regulates Akt and GSK-3 via Dvl-3. Int J Neuropsychopharmacol. 15:965–979. 2012. View Article : Google Scholar : PubMed/NCBI

35 

Castaing M, Loiseau A and Cornish-Bowden A: Synergy between verapamil and other multidrug -resistance modulators in model membranes. J Biosci. 32:737–746. 2007. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

February 2017
Volume 37 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, C., Gong, P., Liu, P., Zhou, N., Zhou, Y., & Wang, Y. (2017). Thioridazine elicits potent antitumor effects in colorectal cancer stem cells. Oncology Reports, 37, 1168-1174. https://doi.org/10.3892/or.2016.5313
MLA
Zhang, C., Gong, P., Liu, P., Zhou, N., Zhou, Y., Wang, Y."Thioridazine elicits potent antitumor effects in colorectal cancer stem cells". Oncology Reports 37.2 (2017): 1168-1174.
Chicago
Zhang, C., Gong, P., Liu, P., Zhou, N., Zhou, Y., Wang, Y."Thioridazine elicits potent antitumor effects in colorectal cancer stem cells". Oncology Reports 37, no. 2 (2017): 1168-1174. https://doi.org/10.3892/or.2016.5313